Different studies demonstrate that growth factors, hormones and cytokines produced by the tumor microenvironment play pivotal roles in the progression of ER+ BC, and many of these signaling pathways can directly affect the transcriptional activity and function of ER, independently by the classical estrogenic ligands. The gene discussed is ESR1; the disease is neoplasm.